Kim Dong 4/A
4/A · UroGen Pharma Ltd. · Filed Feb 12, 2024
Insider Transaction Report
Form 4/AAmended
Kim Dong
Chief Financial Officer
Transactions
- Award
Stock Option (right to buy)
2022-03-25+20,000→ 20,000 totalExercise: $8.61Exp: 2032-03-25→ Ordinary Shares (20,000 underlying)
Footnotes (5)
- [F1]One third of the shares underlying the stock option will vest on each of March 25, 2023, March 25, 2024 and March 25, 2025.
- [F2]This amendment corrects and restates the number of derivative securities acquired reported in the original Form 4 filed on March 29, 2022.
- [F3]This amendment corrects and restates the expiration date reported in the original Form 4 filed on March 29, 2022.
- [F4]This amendment corrects and restates the amount of securities underlying derivative security reported in the original Form 4 filed on March 29, 2022.
- [F5]This amendment corrects and restates the number of derivative securities beneficially owned following reported transaction reported in the original Form 4 filed on March 29, 2022.